

Port
E1

administering to said patient to an effective amount of an agent which is capable of crossing the blood brain barrier, wherein said agent modulates the interaction within the central nervous system between a divalent or trivalent cation and/or heparin with amyloid precursor protein (APP) of said patient, with the proviso that said agent is not EDTA.

35. (new) The method according to claim 34, wherein the cation is a divalent cation.

36. (new) The method according to claim 35, wherein said divalent cation is zinc.

37. (new) The method according to claim 34, wherein said agent is a zinc-binding agent.

38. (new) The method according to claim 37, wherein said zinc-binding agent is selected from sodium citrate, 1,2-diethyl-3-hydroxypyridin-4-one, and 1-hydroxyethyl-3-hydroxy-2-methylpyridin-4-one.

39. (new) The method according to claim 37, wherein said zinc-binding agent is orally administered to said patient.

40. (new) A method of reducing incorrect protease-mediated processing of amyloid precursor protein (APP) in a patient with Alzheimer's disease comprising the step of administering said patient to an effective amount of an agent which is capable of crossing the blood brain barrier, wherein said agent modulates the interaction within the central nervous system between a divalent or trivalent cation and/or heparin with amyloid precursor protein (APP) of said patient, with the proviso that said agent is not EDTA.

Sub
33

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

Cont
E1

41. (new) The method according to claim 40, wherein the cation is a divalent cation.

42. (new) The method according to claim 41, wherein said divalent cation is zinc.

43. (new) The method according to claim 40, wherein said agent is a zinc-binding agent.

44. (new) The method according to claim 43, wherein said zinc-binding agent is selected from sodium citrate, 1,2-diethyl-3-hydroxypyridin-4-one, and 1-hydroxyethyl-3-hydroxy-2-methylpyridin-4-one.

45. (new) The method according to claim 43, wherein said zinc-binding agent is orally administered to said patient.

REMARKS

I. Status of the Claims

Upon entry of this amendment, claims 28-45 are pending. No new matter has been added. Support for the amendment appears at pages 6-7 of Applicants' specification. Applicants respectfully request entry of the new claims in order to place the application in condition for allowance or in better form for appeal.

New claims 34-45 presented with this submission are different than the claims filed May 20, 2002, and not entered. See Advisory Action mailed May 30, 2002. These new claims differ from the previously submitted claims by containing a proviso to exclude the use of EDTA.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com